GlassScriptPhysician profile
Maria Nickolova
NPI 1093718819
$25,408.94
in general payments reported to CMS, 2019-2025
41 companies · $4,688 in 2025
The $4,688 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,068 · 2020: $2,404 · 2021: $3,685 · 2022: $3,962 · 2023: $3,749 · 2024: $3,853 · 2025: $4,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,290.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,266.27 | 2019-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $2,179.25 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $2,150.94 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $2,149.34 | 2019-2025 | Rexulti, Brintellix |
| Vanda Pharmaceuticals INC. | $1,777.04 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $1,682.84 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,592.10 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,535.49 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,473.61 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $1,036.94 | 2019-2022 | |
| Axsome Therapeutics, INC. | $958.76 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $948.68 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $868.05 | 2019-2025 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $512.32 | 2021-2025 | Qelbree |
| Corium, LLC | $509.53 | 2022-2025 | Azstarys |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $479.76 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $407.77 | 2022-2024 | Quviviq |
| Allergan, INC. | $406.14 | 2019-2020 | |
| Neos Therapeutics, LP | $361.08 | 2019-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $309.29 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $279.36 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $239.66 | 2019-2023 | Belsomra |
| Almatica Pharma LLC | $207.11 | 2021-2025 | Loreev Xr |
| Eisai INC. | $191.29 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $131.01 | 2025 | Invega Sustenna |
| Avanir Pharmaceuticals, INC. | $117.31 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $109.55 | 2019-2022 | |
| Noven Therapeutics, LLC | $84.10 | 2020-2024 | Xelstrym, Secuado |
| Biogen, INC. | $80.73 | 2023-2025 | Zurzuvae |
| Alfasigma USA, INC. | $62.00 | 2020-2022 | |
| Shire North American Group INC | $39.70 | 2019 | |
| Livanova USA, INC. | $37.56 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Novo Nordisk INC | $36.74 | 2023-2024 | Wegovy |
| Tris Pharma INC | $35.26 | 2020 | |
| Acadia Pharmaceuticals INC | $34.25 | 2021-2023 | Nuplazid |
| Vertical Pharmaceuticals, LLC | $30.48 | 2019 | |
| Neuronetics, INC. | $23.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.23 | 2019 | |
| Luye Pharma (USA) LTD. | $14.34 | 2025 | Erzofri Extended-Release |
| Owp Pharmaceuticals, INC. | $13.93 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Nickolova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.